Q-Biologicals is a privately owned biopharma contract development and manufacturing organization (CDMO), based in Ghent, Flanders, Belgium. A pure-bred contract service provider, we offer a comprehensive range of process development and biomanufacturing services to customers in the biopharmaceutical industry and beyond.
Founded in 2011, Q-Biologicals is built on a strong heritage. Operating personnel and leadership team can rely on 20+ years of experience in biopharmaceutical process development of diagnostics and therapeutics, and have an outstanding track record achieved over 15 years of cGMP manufacturing. From the beginning, the young company was successful in scoring business with several top-ranking pharma multinationals, as well as with emerging biopharmaceutical companies.
Q-Biologicals’ service portfolio can be accessed by ordering integrated development and manufacturing solutions, or through customized modular work packages, tailored to the clients’ needs. Our crew has solid expertise and experience in designing processes for the production of recombinant proteins, vaccines – including viruses, virus-like particles (VLP’s), and live cells – , and monoclonal antibodies.
Services also include production of non-GMP, high-quality research grade biologicals (small and large scale), such as e.g. recombinant proteins or monoclonal antibodies with low endotoxin content.
Last but not least, Q-Biologicals also offers standalone consultancy services, be it from afar, or through on-site troubleshooting. These activities are focused on our manufacturing expertise, and cover process and analytical method design, analysis or validation, CMC regulatory documentation, or QC and QA support.
Q-Biologicals operates two facilities, housed on separate floors. One floor is dedicated in its entirety to non-GMP research work. The second floor harbours several state-of-the art cGMP biomanufacturing suites, operating under BSL2 containment level.
The company’s entire portfolio of services is embedded in high-level Quality Management (ISO:9001 and cGMP). The segregation in the facility set-up allows for maximum flexibility, enabling us to serve research and development clients alike, with offerings tailored to your respective needs and Quality requirements.
Q-Biologicals has a network of carefully selected technology partnerships. These strategic alliances enable our clients to access innovative technology, such as high-titre proprietary expression systems, a vaccine platform based on VLP technology, novel purification tools and processes, customized cell lines, or innovative formulation methods.
Find out more at www.q-biologicals.com or come and visit us in Ghent!